Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-165.67M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.09 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -137.70% |
| Return on Assets (Trailing 12 Months) | -101.43% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.73 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 103.88M |
| Free Float | 99.21M |
| Market Capitalization | $498.64M |
| Average Volume (Last 20 Days) | 1.52M |
| Beta (Past 60 Months) | 1.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |